Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancer BriaCell Phase 3 trialfeatured in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026” PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. …
Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell’s ongoing pivotal Phase 3 study in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: …
Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US Kaleio to support brand strategies and customized commercial-readiness solutions Bria-IMT is currently being evaluated in Bria-Cell’s ongoing pivotal Phase 3 study in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, July 07, …
Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell’s pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the patient and provider experience Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study in advanced …
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering …
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3 TWiST analysis, which measures time without disease symptoms or significant treatment-related toxicity, showed clinically meaningful benefit in heavily pre-treated MBC patients in the ongoing Phase 3 …
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an …
Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Sixth consecutive positive DSMB recommendation to proceed highlights the favorable safety and tolerability of BriaCell’s novel immunotherapy approach Phase 3 study is being conducted under FDA Fast Track Designation, reflecting …
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) patients Biomarker analyses from the ongoing Phase 3 study confirm predictors of anti-cancer response seen in Phase 2 PHILADELPHIA and VANCOUVER, …
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancer Bria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumor activity Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in …